Eric S. Wang
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
- Hematology top 5%
Papers in
- Oncology 9
- CAR-T cell therapy research 4
- Cancer Immunotherapy and Biomarkers 4
- Lung Cancer Research Studies 2
-
- Protein Degradation and Inhibitors 13
- Ubiquitin and proteasome pathways 9
- Co-authors
- Nathanael S. Gray (11 shared papers)Katherine A. Donovan (9 shared papers)Eric S. Fischer (9 shared papers)Tinghu Zhang (4 shared papers)Baishan Jiang (2 shared papers)Yanke Liang (2 shared papers)Radosław P. Nowak (6 shared papers)Nicholas P. Kwiatkowski (2 shared papers)
- Journals
- Cell chemical biology (3 papers)ACS Chemical Biology (2 papers)Cancer Discovery (2 papers)Nature Chemical Biology (2 papers)Angewandte Chemie International Edition (2 papers)
- Partner nations
- United StatesSouth KoreaHong Kong
In The Last Decade
Eric S. Wang
22 papers receiving 2.2k citations
Eric S. Wang's Hit Papers
Peers
Comparison fields: 5 of 80
- Oncology 1.2k
- Hematology 218
- Immunology 382
- Pulmonary and Respiratory Medicine 499
- Genetics 167
Countries citing papers authored by Eric S. Wang
This map shows the geographic impact of Eric S. Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric S. Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric S. Wang more than expected).
Fields of papers citing papers by Eric S. Wang
This network shows the impact of papers produced by Eric S. Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric S. Wang. The network helps show where Eric S. Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Eric S. Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation Hit paper breakdown → | 2017 | 619 |
| 2 | Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids Hit paper breakdown → | 2017 | 484 |
| 3 | 2019 | 241 | |
| 4 | 2018 | 222 | |
| 5 | 2019 | 166 | |
| 6 | 2018 | 147 | |
| 7 | 2021 | 112 | |
| 8 | 2021 | 94 | |
| 9 | 2020 | 73 | |
| 10 | 2018 | 71 | |
| 11 | 2023 | 25 | |
| 12 | 2022 | 12 | |
| 13 | 2022 | 12 | |
| 14 | 2022 | 9 | |
| 15 | 2006 | 6 | |
| 16 | 2011 | 5 | |
| 17 | 2016 | 5 | |
| 18 | 2023 | 4 | |
| 19 | 2023 | 4 | |
| 20 | 2025 | 3 |
About Eric S. Wang
Eric S. Wang is a scholar working on Oncology, Molecular Biology, Hematology, Cell Biology and Immunology, having authored 22 papers that have together received 2.3k indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (13 papers), Ubiquitin and proteasome pathways (9 papers), CAR-T cell therapy research (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Multiple Myeloma Research and Treatments (3 papers), Lung Cancer Research Studies (2 papers), Autophagy in Disease and Therapy (2 papers) and Advanced Breast Cancer Therapies (2 papers). The work is most often cited by research in Oncology (1.2k citations), Hematology (218 citations), Immunology (382 citations), Pulmonary and Respiratory Medicine (499 citations) and Genetics (167 citations). Eric S. Wang has collaborated with scholars based in United States, South Korea and Hong Kong. Frequent co-authors include Nathanael S. Gray, Katherine A. Donovan, Eric S. Fischer, Tinghu Zhang, Baishan Jiang, Yanke Liang, Radosław P. Nowak, Nicholas P. Kwiatkowski, Jingting C. Yuan and Matthias Brand. Their work appears in journals such as Cell chemical biology, ACS Chemical Biology, Cancer Discovery, Nature Chemical Biology and Angewandte Chemie International Edition.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.